Renal allografts retained in situ after failure

Archives of Surgery
H SilbermanT V Berne

Abstract

Twenty-four renal allografts functioning up to six years from the date of transplantation were retained in situ from four days to five years following return of the patient to hemodialysis. Fifteen of the 24 kidneys were removed for specific indications within four days to ten months. The reasons for allograft nephrectomy included fever, hematuria, graft pain and tenderness, and severe hypertension. Nine patients remained asymptomatic with grafts retained three months to five years (median, two years) following return to hemodialysis. It appears safe to retain nonfunctioning grafts in asymptomatic patients, thereby avoiding an unnecessary operation when failure is due to chronic rejection or recurrent glomerulonephritis. Nevertheless, in many patients complications eventually develop for which the allograft will be removed.

Citations

Oct 31, 2009·Journal of the American Society of Nephrology : JASN·Juan Carlos AyusAlan S Go
Aug 13, 2003·The Journal of Urology·Eduardo MazzucchiSami Arap
Aug 23, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Patricia DelgadoVictor Lorenzo
Dec 16, 2004·Pediatric Transplantation·F ZeroualiL A H Monnens
Aug 2, 2011·Seminars in Dialysis·William S Asch, Margaret Bia
May 20, 2015·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Edward J Filippone, John L Farber
Jan 1, 1986·Scandinavian Journal of Urology and Nephrology·B Lund HansenS A Birkeland
Jan 22, 2008·Urologia Internationalis·Samiran Das AdhikaryGanesh Gopalakrishnan
Jun 7, 2005·Seminars in Dialysis·Juan Carlos Ayus, Steven G Achinger
Jul 1, 1982·The Journal of Urology·D H EvansF C Whittier
Apr 1, 1994·The Journal of Urology·D C O'SullivanM G Donovan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.